FDA approves Eli Lilly’s Kisunla for Alzheimer’s treatment

The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer's treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically ... Read More